University of Minnesota has divulged nonstructural protein 14 (NSP14) (SARS-CoV-2) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection.
Researchers at Centre Hospitalier de Université de Montréal and University of Pennsylvania have identified compounds reported to be useful for the treatment of HIV-1 infection.
Xiamen University has synthesized oligopeptides targeting β2-microglobulin (B2M) reported to be useful for the treatment of cancer and Alzheimer’s disease.
Jazz Pharmaceuticals plc has disclosed macrocyclic orexin OX2 receptor agonists reported to be useful for the treatment of hypersomnia, narcolepsy and sleep disorders.
Immunoscape Pte Ltd. and Mink Therapeutics Inc. have entered into a collaboration agreement to discover and develop next-generation T-cell receptor (TCR) therapies against novel targets in solid tumors.
MYB is a transcription factor essential for cell proliferation and differentiation, and is regarded as a target for cancer therapy because it is overexpressed in many different tumor types such as adenoid cystic carcinoma (ACC), acute myeloid leukemia (AML) or T-cell acute lymphoblastic leukemia, among others.
Sudo Biosciences Inc. has closed a $116 million series B financing, with the funding raised to be used to advance two investigational TYK2 candidates into the clinic in 2024.
The FDA has awarded orphan drug designation to Ocelot Bio Inc.'s lead candidate OCE-205 for the treatment of ascites due to all etiologies except cancer. Ocelot Bio plans to initiate clinical studies of OCE-205 in refractory ascites next year.
Researchers have developed a novel chronic lymphocytic leukemia (CLL) murine model that expresses human BCL2 in B cells under the TCL1 promoter control, named TBC.
RSS
